Literature DB >> 22029521

Immunomodulatory therapy for sepsis: an update.

Eirini Christaki1, Panagiota Anyfanti, Steven M Opal.   

Abstract

Currently the treatment mainstay of sepsis is early and appropriate antibiotic therapy, accompanied by aggressive fluid administration, the use of vasopressors when needed and the prompt initiation of measures to support each failing organ. Activated protein C and hydrocortisone, when used accordingly can affect mortality. As the pathophysiologic events that take place during sepsis are being elucidated, new molecules that target each step of those pathways are being tested. However, a lot of those molecules affect various mediators of the sepsis cascade including inflammatory cytokines, cellular receptors, nuclear transcription factors, coagulation activators and apoptosis regulators. Over the last decade, a multitude of clinical trials and animal studies have investigated strategies that aimed to restore immune homeostasis either by reducing inflammation or by stimulating the innate and adaptive immune responses. Antibiotics, statins and other molecules with multipotent immunomodulatory actions have also been studied in the treatment of sepsis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22029521     DOI: 10.1586/eri.11.122

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  21 in total

1.  Live liver donors: Are they at a higher risk for post-operative thrombotic complications?

Authors:  Ibtesam Abbass Hilmi; Raymond M Planinsic
Journal:  World J Transplant       Date:  2012-02-24

2.  Inhibition of hepatic cells pyroptosis attenuates CLP-induced acute liver injury.

Authors:  Yuan-Li Chen; Guo Xu; Xiao Liang; Juan Wei; Jing Luo; Guan-Nan Chen; Xiao-Di Yan; Xue-Ping Wen; Ming Zhong; Xin Lv
Journal:  Am J Transl Res       Date:  2016-12-15       Impact factor: 4.060

3.  Protective role of tenuigenin on sepsis-induced acute kidney injury in mice.

Authors:  Yan Xu; Yan Jiang; Wentao Gai; Botao Yu
Journal:  Exp Ther Med       Date:  2017-09-21       Impact factor: 2.447

4.  New approaches to sepsis: molecular diagnostics and biomarkers.

Authors:  Konrad Reinhart; Michael Bauer; Niels C Riedemann; Christiane S Hartog
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

Review 5.  Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach.

Authors:  Richard S Hotchkiss; Guillaume Monneret; Didier Payen
Journal:  Lancet Infect Dis       Date:  2013-03       Impact factor: 25.071

Review 6.  Antimicrobial Therapy in the Context of the Damage-Response Framework: the Prospect of Optimizing Therapy by Reducing Host Damage.

Authors:  Liise-Anne Pirofski; Arturo Casadevall
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

7.  Broad spectrum immunomodulation using biomimetic blood cell margination for sepsis therapy.

Authors:  Han Wei Hou; Lidan Wu; Diana P Amador-Munoz; Miguel Pinilla Vera; Anna Coronata; Joshua A Englert; Bruce D Levy; Rebecca M Baron; Jongyoon Han
Journal:  Lab Chip       Date:  2016-01-15       Impact factor: 6.799

8.  Effects of simvastatin on the expression of inducible NOS in acute lung injury in septic rats.

Authors:  Wei-Chao Li; Zi-Jun Zou; Ming-Gen Zhou; Liang Chen; Lin Zhou; Yu-Kai Zheng; Zhi-Jie He
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

9.  Analysis of Flavonoids from Eugenia uniflora Leaves and Its Protective Effect against Murine Sepsis.

Authors:  Yanna D Rattmann; Lauro Mera de Souza; Simone M Malquevicz-Paiva; Nessana Dartora; Guilherme Lanzi Sassaki; Philip A J Gorin; Marcello Iacomini
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-20       Impact factor: 2.629

10.  Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice.

Authors:  Marcel Leist; Thomas Hartung
Journal:  Arch Toxicol       Date:  2013-03-19       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.